Cardiovascular Engineering

What Cardiovascular Engineering does

Cardiovascular Engineering, Inc. (CEI) is a privately held, Needham, Massachusetts-based medical device company founded in 1998 that develops non-invasive systems for assessing arterial stiffness and cardiovascular health. The company's core offering is a proprietary AI-driven platform that analyzes arterial pressure waveforms to derive aortic-stiffness measurements and a "VascularAge" metric, which CEI reports is highly predictive of adverse cardiometabolic and cardiovascular disease outcomes. Its product portfolio spans the NIHem PPG (an FDA-cleared photoplethysmography waveform acquisition module), NIHem BT (a research-grade arterial tonometry data acquisition and analysis system), Waveform AI (the machine-learning engine that translates waveforms into physiologic insights), and NIHem Mobile (a consumer-facing application for ongoing cardiometabolic monitoring). The integrated pipeline moves from hardware data acquisition (PPG, tonometry) through AI-powered analysis (Waveform AI) to a consumer mobile interface (NIHem Mobile).

The company serves three customer segments: healthcare providers and medical institutions (the primary vertical), research institutions requiring research-grade arterial tonometry, and individual consumers using the NIHem Mobile application. Revenue mechanics are diversified across medical-device hardware sales, recurring software/AI services tied to the Waveform AI platform, and one-time research-grade product licenses. Pricing is not publicly disclosed and follows a quote-based, direct-sales model with inquiries routed via email ([email protected]) and the corporate website (ceibio.com).

Go-to-market is executed through direct enterprise sales targeting healthcare and research buyers, supported by a minimal public footprint consisting of a product website and a LinkedIn company page. The company has 11–50 employees, has not disclosed any funding rounds, partnerships, named customers, or patent portfolio in the available data, and reports a regulatory milestone (FDA clearance for NIHem PPG under 21 CFR Part 11) as its principal externally verifiable achievement.

Name

Cardiovascular Engineering

Legal name

Cardiovascular Engineering, Inc.

Website

https://cardiovascularengineering.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Cardiovascular Engineering, Inc. is a Needham, MA-based medical device company founded in 1998 that develops FDA-cleared and research-grade non-invasive systems for assessing arterial stiffness and cardiovascular health using proprietary AI-powered arterial pressure waveform analysis.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), ECG/EKG & Heart Rhythm Monitors (Consumer) (CRACAQAC)

Keywords

• Non-invasive cardiovascular diagnostics
• Arterial waveform analysis
• Medical device manufacturing
• Photoplethysmography devices
• Vascular health monitoring

Headquarters

HQ city

Norwood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of FDA-cleared and research-grade medical devices including NIHem PPG and NIHem BT hardware products
2. Software/AI Services: Waveform AI technology translating waveforms into physiologic insights; NIHem Mobile app for ongoing health monitoring
3. Research-grade Products: Sale of research-grade arterial tonometry equipment to research institutions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Cardiovascular Engineering, Inc. (CEI) develops and sells non-invasive medical devices and AI software for assessing arterial stiffness and cardiovascular health. Its core product line includes the FDA-cleared NIHem PPG (photoplethysmography waveform acquisition module), the NIHem BT research-grade arterial tonometry system, the NIHem Mobile consumer health monitoring app, and its proprietary Waveform AI engine that translates arterial pressure waveforms into physiologic insights including VascularAge and aortic stiffness metrics.

Product overview

Cardiovascular Engineering offers a unified product portfolio centered on AI-powered waveform analysis. The core offerings include NIHem PPG (FDA-cleared PPG acquisition), NIHem BT (research-grade arterial tonometry), and Waveform AI (the AI engine that translates waveforms into physiologic insights including VascularAge assessment). NIHem Mobile extends these capabilities to consumer mobile monitoring. Together, these products form an integrated pipeline from data acquisition (PPG, BT) through AI-powered analysis (Waveform AI) to mobile health monitoring (NIHem Mobile).

Differentiator

Problem solved

Functional benefit

Brands

• NIHem: Product brand for medical devices including NIHem PPG (FDA-cleared PPG waveform acquisition module), NIHem BT (research-grade arterial tonometry data acquisition and analysis), and NIHem Mobile (cardiometabolic health monitoring app)

Products and services

• NIHem PPG FDA-cleared photoplethysmography (PPG) waveform acquisition module that captures pulse wave data for use with the company's Waveform AI analytics; intended for healthcare providers and clinical settings performing cardiometabolic and cardiovascular risk assessment.
• NIHem BT Research-grade arterial tonometry data acquisition and analysis system that delivers high-fidelity pressure waveform measurement for vascular and cardiovascular physiology research; targeted at academic, clinical, and industry research laboratories studying aortic stiffness and vascular aging.
• Waveform AI AI-powered software platform that translates arterial pressure waveforms into physiologic insights using machine learning; assesses aortic stiffness and computes VascularAge from uncalibrated pressure waveforms, and is described as highly predictive of adverse cardiometabolic and cardiovascular outcomes. Used by healthcare providers and researchers analyzing data captured by NIHem PPG and NIHem BT.
• NIHem Mobile Mobile application that allows individual users to monitor their own cardiometabolic health and track cardiovascular risk metrics; positioned as the consumer-facing endpoint of CEI's data-acquisition-to-insight pipeline.

Quantifiable outcome

• VascularAge is highly predictive of adverse cardiometabolic and cardiovascular disease outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Emerging players

• Withings: Withings produces consumer connected-health devices (BPM Core, ScanWatch, Body Scan) that capture PPG and ECG signals and surface cardiovascular metrics in a companion app. It overlaps with CEI's NIHem Mobile/Pulse-style consumer PPG-based cardiovascular risk offering.

Direct peers

• CardieX: CardieX develops consumer and clinical arterial health monitoring devices (CONNEQT, Arty) that derive cardiovascular insights from arterial waveforms and PPG. It competes with CEI in the same VascularAge/arterial-health positioning across both provider and consumer segments.
• Itamar Medical (ZOLL/Asahi Kasei): Itamar Medical builds FDA-cleared non-invasive vascular diagnostic devices (WatchPAT, EndoPAT) used in cardiology and sleep medicine. It overlaps with CEI in non-invasive vascular diagnostics and cardiology-focused clinical sales channels.
• USCOM: USCOM produces a non-invasive cardiac output monitor based on arterial pressure waveform analysis. It shares both the underlying physiologic signal (arterial pressure waveform) and the non-invasive hemodynamic-monitoring clinical use case.
• Finapres Medical Systems: Finapres manufactures Finapres Nova and Portapres, non-invasive continuous hemodynamic monitoring devices using finger-cuff arterial waveform technology, positioned similarly to NIHem BT in research-grade arterial pressure measurement.
• iRhythm Technologies: iRhythm applies AI to continuous ambulatory cardiac monitoring via the Zio patch, combining a wearable hardware device with a cloud-based AI analytics service. Its hardware-plus-AI-service business model closely mirrors CEI's NIHem PPG + Waveform AI + NIHem Mobile stack.
• AtCor Medical (SunTech Medical): AtCor pioneered the SphygmoCor system for non-invasive measurement of central blood pressure and arterial stiffness, the same clinical problem CEI's Waveform AI targets. As the historical gold standard in pulse-wave analysis, it is the most directly comparable peer to CEI's NIHem platform.

Broad incumbents

• GE HealthCare: GE HealthCare manufactures a wide range of cardiovascular diagnostic and monitoring equipment, including hemodynamic monitors used in acute care. Its broad portfolio competes with CEI for hospital- and clinic-level cardiovascular monitoring spend.
• Edwards Lifesciences: Edwards is a major cardiovascular device company with a hemodynamic monitoring franchise (FloTrac, ClearSight) spanning invasive and non-invasive monitoring. While much larger and broader, its hemodynamic monitoring line directly overlaps CEI's clinical positioning.
• Philips (Cardiovascular Care): Philips provides a broad portfolio of cardiac and hemodynamic monitoring solutions within its connected care and cardiology businesses. As a large incumbent, it competes for hospital budgets and clinical workflow integration that CEI also targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/cardiovascular-engineering-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiovascular Engineering